{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-060529","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.035272+00:00","generated_at":"2026-06-02T02:00:46.073397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24","bullets":["Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.","Cash & marketable securities $69.8M at March 31, 2024, down from $100.8M at Dec 31, 2023; ops used $30.5M.","KOURAGE 1 Part A topline NP results expected by end of Q2 2024; 214 patients enrolled, not powered for significance.","KORSUVA injection net sales $1.8M in Q1 2024; TDAPA expired March 31, now reimbursed via ESRD bundle.","Restructuring expenses $2.4M related to workforce reduction; R&D $22.0M vs $24.3M a year ago."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-060529","json":"https://secwatch.observer/filing/0001104659-24-060529.json","markdown":"https://secwatch.observer/filing/0001104659-24-060529.md","text":"https://secwatch.observer/filing/0001104659-24-060529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/0001104659-24-060529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/tm2414193d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:00:46.073397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25fbe0016cb4fb4124edab89c29f31039533894b","claim":"Tvardi Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $2.1 million, net income $30.7 million, EPS $(0.56) per basic and diluted share.","evidence_excerpt":"or $(0.56) per basic and diluted share, compared to net loss of $26.7 million, or ($0.49) per basic and diluted share, for the same period in 2023. Revenues: Total revenue was $2.1 million and $6.2 million for the three months ended March 31, 2024 and 2023, respectively. Revenue primarily consisted of: · $0.8 million and $2.8 million of collaborative revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924060529/0001104659-24-060529-index.htm","confidence":0.999,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$2.1 million"},{"label":"Net income","value":"$30.7 million"},{"label":"EPS","value":"$(0.56) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}